E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells

Cancer Gene Therapy

Volumn 11, Issue 9, 2004, Pages 585-593

  Rao, Xiao Mei ^a   Tseng, Michael T ^a   Zheng, Xinyu ^a   Dong, Yanbin ^a   Jamshidi Parsian, Azemat ^a   Thompson, Timothy C ^b   Brenner, Malcolm K ^c   McMasters, Kelly M ^a   Zhou, Heshan Sam ^a  

^a University of Louisville School of Medicine   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Adenovirus replication; Apoptosis; E1A; E1B

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL NUCLEUS; CELL PROTECTION; CHROMATIN CONDENSATION; CONTROLLED STUDY; DNA DEGRADATION; EMBRYO; GENE DELETION; GENE THERAPY; HUMAN; HUMAN CELL; LIFE CYCLE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE INFECTIONS; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ADENOVIRUSES, HUMAN; APOPTOSIS; BLOTTING, WESTERN; CHROMATIN; DNA, VIRAL; GENE DELETION; GENETIC VECTORS; HUMANS; LUNG NEOPLASMS; MICRONUCLEI, CHROMOSOME-DEFECTIVE; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 4444221306     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700739     Document Type: Article

References (46)

1. Nevins JR, Leone G, DeGregori J, Jakoi L. Role of the Rb/ E2F pathway in cell growth control. J Cell Physiol. 1997;173:233-236.
2. O'Connor RJ, Hearing P. The E4-6/7 protein functionally compensates for the loss of E1A expression in adenovirus infection. J Virol. 2000;74:5819-5824.
3. Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev. 1997;11:1853-1863.
4. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781-787.
5. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med. 2002;80:163-175.
6. Debbas M, Blanchette P, Yan Q, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 1993;7:546-554.
7. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 1993;7:535-545.
8. Kao CC, Yew PR, Berk AJ. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology. 1990;179:806-814.
9. Martin ME, Berk AJ. Adenovirus E1B 55K represses p53 activation in vitro. J Virol. 1998;72:3146-3154.
10. Grand RJ, Grant ML, Gallimore PH. Enhanced expression of p53 in human cells infected with mutant adenoviruses. Virology. 1994;203:229-240.
11. Querido E, Blanchette P, Yan Q, et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001;15:3104-3117.
12. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene. 1998;16:349-357.
13. Rao L, Debbas M, Sabbatini P, et al. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA. 1992;89:7742-7746.
14. Cuconati A, Degenhardt K, Sundararajan R, Anschel A, White E. Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol. 2002;76:4547-4558.
15. Bischoff JR, Kim DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
16. Kirn D. Clinical research results with d11520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy. 2001;8:89-98.
17. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Therapy. 2001;8:746-759.
18. Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 2002;62:764-772.
19. Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer. 2002;86:5-11.
20. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments). Nat Med. 1997;3:639-645.
21. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000;60: 1193-1196.
22. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol. 1998;72:9470-9478.
23. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol. 1998;72:9479-9490.
24. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55 K in adenovirus type 5 replication. J Virol. 1999;73:5333-5344.
25. Edwards SJ, Dix BR, Myers CJ, et al. Evidence that replication of the antitumor adenovirus onyx-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol. 2002;76:12483-12490.
26. Dix BR, Edwards SJ, Braithwaite AW. Does the antitumor adenovirus ONYX-015/d11520 selectively target cells defective in the p53 pathway? J Virol. 2001;75: 5443-5447.
27. Zhao T, Rao XM, Xie X, et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res. 2003;63: 3073-3078.
28. Hay JG, Shapiro N, Sauthoff H, et al. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum Gene Ther. 1999;10:579-590.
29. Sauthoff H, Heitner S, Rom WN, Hay JG. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther. 2000;11: 379-388.
30. Harrison D, Sauthoff H, Heitner S, et al. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther. 2001;12: 1323-1332.
31. Kim J, Cho JY, Kim JH, Jung KC, Yun CO. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 2002;9:725-736.
32. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-72.
33. Lehman TA, Benett WP, Metcalf RA, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991;51: 4090-4096.
34. Bett AJ, Haddara W, Prevec L, Graham FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
35. Graham FL. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology. Vol. 7 Clifton, NJ: The Humana Press Inc.; 1991 pp 109-128.
36. Zhou H, O'Neal W, Morral N, Beaudet AL. Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol. 1996;70:7030-7038.
37. Tseng MT, Safa AR. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10- anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride. Cancer Res. 1983;43:5910-5914.
38. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000;290:989-992.
39. Theodorakis P, Lomonosova E, Chinnadurai G. Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res. 2002;62:3373-3376.
40. Yu DH, Scorsone K, Hung MC. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol. 1991;11:1745-1750.
41. Yu D, Suen TC, Yan DH, Chang LS, Hung MC. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA. 1990;87:4499-4503.
42. Yu D, Matin A, Xia W, et al. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995;11:1383-1388.
43. Frisch SM. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc Natl Acad Sci USA. 1991;88: 9077-9081.
44. Deng J, Xia W, Hung MC. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene. 1998;17:2167-2175.
45. Yoo GH, Hung MC, Lopez-Berestein G, et al. Phase I trial of intratumoral liposome e1a gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001;7:1237-1245.
46. Villaret D, Glisson B, Kenady D, et al. A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck. 2002;24:661-669.